RS20050752A - Combination of a macrolide and a local anesthetic for the treatment of dermatological diseases - Google Patents

Combination of a macrolide and a local anesthetic for the treatment of dermatological diseases

Info

Publication number
RS20050752A
RS20050752A YUP-2005/0752A YUP20050752A RS20050752A RS 20050752 A RS20050752 A RS 20050752A YU P20050752 A YUP20050752 A YU P20050752A RS 20050752 A RS20050752 A RS 20050752A
Authority
RS
Serbia
Prior art keywords
macrolide
treatment
dermatological diseases
combination
local anesthetic
Prior art date
Application number
YUP-2005/0752A
Other languages
English (en)
Inventor
Maximilian Grassberger
Stefan Hirsch
Nabila Sekkat
Carl Martin Weiss
Original Assignee
Novartis Ag.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag., filed Critical Novartis Ag.,
Publication of RS20050752A publication Critical patent/RS20050752A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Opisane su sinergističke kombinacije makrolidnog imunomodulatora i imunosupresora T-ćelija, kao što je 33-epihloro-33-dezoksiaskomicin I lokalnog anestetika, kao što je lidokain, polidokanol ili prilokain, koje su naročito korisne u lečenju dermatoloških oboljenja kao što su atopični, kontaktni ili seboreični dermatitis, psorijaza, akne, rozacea, faza post-perutanja, pruritus, osećaj pečenja na koži ili svraba; i prateći bol.
YUP-2005/0752A 2003-04-04 2004-04-02 Combination of a macrolide and a local anesthetic for the treatment of dermatological diseases RS20050752A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307869.8A GB0307869D0 (en) 2003-04-04 2003-04-04 Pharmaceutical composition
PCT/EP2004/003515 WO2004087144A1 (en) 2003-04-04 2004-04-02 Combination of a macrolide and a local anesthetic for the treatment of dermatological diseases

Publications (1)

Publication Number Publication Date
RS20050752A true RS20050752A (en) 2007-11-15

Family

ID=9956231

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0752A RS20050752A (en) 2003-04-04 2004-04-02 Combination of a macrolide and a local anesthetic for the treatment of dermatological diseases

Country Status (13)

Country Link
US (1) US20060110448A1 (sr)
EP (1) EP1613317A1 (sr)
JP (1) JP2006522061A (sr)
CN (1) CN1771036A (sr)
AU (1) AU2004226823A1 (sr)
BR (1) BRPI0409207A (sr)
CA (1) CA2521261A1 (sr)
GB (1) GB0307869D0 (sr)
IS (1) IS8106A (sr)
MX (1) MXPA05010709A (sr)
NO (1) NO20055137L (sr)
RS (1) RS20050752A (sr)
WO (1) WO2004087144A1 (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
KR102141441B1 (ko) * 2018-06-28 2020-08-05 이환석 무출혈 무통필름
CN108853312B (zh) * 2018-09-25 2021-04-16 陕西天宇制药有限公司 聚桂醇外用凝胶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB766245A (en) * 1954-09-03 1957-01-16 Lilly Co Eli Therapeutic preparations containing erythromycin
HU194493B (en) * 1985-11-27 1988-02-29 Chinoin Gyogyszer Es Vegyeszet Process for preparing primycin-containing colloidal basic gel and compositions comprising the same
JPH08133979A (ja) * 1994-09-16 1996-05-28 Sando Yakuhin Kk 局所適用薬剤組成物
BR9509530A (pt) * 1994-10-26 1997-10-14 Novartis Ag Composições farmacêuticas
CN1158258A (zh) * 1996-12-11 1997-09-03 李志辉 秦云创伤外用药
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6120792A (en) * 1998-04-29 2000-09-19 Juni; Jack E. Medicated skin patch and method for its use
JP2001288086A (ja) * 1999-07-21 2001-10-16 Shoei:Kk 皮膚疾患の治療用又は予防用外用剤
JP2001288085A (ja) * 1999-07-21 2001-10-16 Shoei:Kk 乾癬の治療用又は予防用外用剤
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
WO2002062353A1 (en) * 2001-02-05 2002-08-15 Marie Madeline Wharton Composition containing sucrafate and a topical anesthetic for human and animals and method of use thereof
RU2195279C1 (ru) * 2001-07-10 2002-12-27 Тульский государственный университет Способ лечения отморожений
CN1189193C (zh) * 2001-09-10 2005-02-16 黄家伶 烧伤药膏
CN1197576C (zh) * 2002-08-30 2005-04-20 孙万一 治疗性病疣的药物及其制备方法

Also Published As

Publication number Publication date
GB0307869D0 (en) 2003-05-14
CN1771036A (zh) 2006-05-10
MXPA05010709A (es) 2005-12-12
US20060110448A1 (en) 2006-05-25
IS8106A (is) 2005-10-31
AU2004226823A1 (en) 2004-10-14
NO20055137L (no) 2006-01-04
BRPI0409207A (pt) 2006-03-28
JP2006522061A (ja) 2006-09-28
CA2521261A1 (en) 2004-10-14
EP1613317A1 (en) 2006-01-11
NO20055137D0 (no) 2005-11-02
WO2004087144A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
MX2009006007A (es) Profarmacos y metodos para hacer y usar los mismos.
WO2004093814A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
PT1420801E (pt) Utilização de fucanos no tratamento de adesões, artrite e psoríase
NO20055136L (no) Farmasoytisk sammensetning som innbeffatter et immunosuppressivt stoff for bruk ved behandling av hudsykdommer
MXPA05011656A (es) Combinaciones para el tratamiento de enfermedades que implican proliferacion, migracion o apoptosis celulares de celulas de mieloma, o angiogenesis.
TW200503751A (en) Methods for treating sinus headache
WO2009061916A3 (en) Benzodiazepinone compounds useful in the treatment of skin conditions
WO2001078706A3 (en) Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
WO2007112453A3 (en) Methods amd compositions for treating conditions
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
WO2008058210A3 (en) Local administration of gallium compositions to treat pain
ATE253939T1 (de) Pharmazeutische zusammensetzung enthaltend einen squalenepoxidasehemmer und einen makrolid- immunomodulator
RS20050752A (en) Combination of a macrolide and a local anesthetic for the treatment of dermatological diseases
WO2004058329A3 (en) Ester combination local anesthetic
WO2008049903A3 (en) Wide-area parasystemic treatment of skin related conditions
WO2004105689A3 (en) Topical composition for the treatment of skin disorders and methods of using the same
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
WO2005016381A3 (en) Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
BRPI0415225A (pt) composições tópicas compreendendo telmesteìna para o tratamento de distúrbios dermatológicos
NO20055179L (no) Synergistiske kombinasjoner av makrolid T-celle modulator eller immunosupressivt stoff og et retionid
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
AU2018288715A1 (en) NK-92 cells and IL-15 agonist combination therapy
RS20050723A (en) Organic compounds